An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer Kuo, T., Cabebe, E. C., Koong, A., NORTON, J. A., Kunz, P. L., Ford, J. M., KAISER, H. L., Rogers, J., Sikic, B. I., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY. 2008

View details for Web of Science ID 000208457401374